相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli
Mariana Albano et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison to Disk Diffusion to Broth Microdilution
C. Paul Morris et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Population Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
Nao Kawaguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units
Alyssa R. Golden et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2020)
Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
Alejandro Iregui et al.
MICROBIAL DRUG RESISTANCE (2020)
Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia
Shio-Shin Jean et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion
Akito Kawai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
Mercedes Delgado-Valverde et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia
M. Biagi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region
Brian D. Johnston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany
Michael Kresken et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
Shazad Mushtaq et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3
Saquib Malik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
Shuhei Matsumoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
Naoki Kohira et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study
Takafumi Sato et al.
JAC-ANTIMICROBIAL RESISTANCE (2020)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program
Daniel J. Diekema et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship
Shio-Shin Jean et al.
DRUGS (2019)
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Takayuki Katsube et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
Rio Nakamura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Takafumi Sato et al.
CLINICAL INFECTIOUS DISEASES (2019)
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
CLINICAL INFECTIOUS DISEASES (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
Sean M. Stainton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
Michael R. Jacobs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
Christopher Longshaw et al.
Open Forum Infectious Diseases (2019)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
James A. Karlowsky et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Krystyna M. Kazmierczak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstreann infections in Taiwan
Shun-Chung Hsueh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
Nao Kawaguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters
Takayuki Katsube et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Toshiaki Aoki et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
Islam M. Ghazi et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
Akinobu Ito et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
Islam M. Ghazi et al.
PHARMACOLOGY (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
Takayuki Katsube et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
J. Dobias et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
Antoni Torres et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
Matthew E. Falagas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
Shuhei Matsumoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol
Sachi Kanazawa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
Naoki Kohira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
Akinobu Ito et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
Akinobu Ito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Tsukasa Ito-Horiyama et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
Andre C. Kalil et al.
CLINICAL INFECTIOUS DISEASES (2016)
Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options
Yoav Golan
BMC INFECTIOUS DISEASES (2015)
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Joanna S. Brooke
CLINICAL MICROBIOLOGY REVIEWS (2012)
分享论文
